UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3668-3675

2005

Volltextzugriff (PDF)

Assessment of the Role of Intraoperative Frozen Section in Guiding Surgical Staging for Endometrial Cancer

International journal of gynecological cancer, 2016-06, Vol.26 (5), p.918-923

2016

Volltextzugriff (PDF)

MRI of ovarian torsion: Correlation of imaging features with the presence of perifollicular hemorrhage and ovarian viability

European journal of radiology, 2016-11, Vol.85 (11), p.2064-2071

2016

Volltextzugriff (PDF)

The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer

Gynecologic oncology, 2007-02, Vol.104 (2), p.401-405

2007

Volltextzugriff (PDF)

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Clinical cancer research, 2022-01, Vol.28 (1), p.36-44

2022

Volltextzugriff (PDF)

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations

Journal of the advanced practitioner in oncology, 2019-07, Vol.10 (5), p.428-439

2019

Volltextzugriff (PDF)

Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma

Modern pathology, 2015-01, Vol.28 (1), p.118-127

2015

Volltextzugriff (PDF)

Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review

Journal of Cancer, 2010-01, Vol.1 (1), p.27-31

2010

Volltextzugriff (PDF)

Tubal origin of ovarian endometriosis

Modern pathology, 2014-08, Vol.27 (8), p.1154-1162

2014

Volltextzugriff (PDF)

Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology

Gynecologic oncology, 2006-07, Vol.102 (1), p.92-97

2006

Volltextzugriff (PDF)

Secretory cell expansion with aging: Risk for pelvic serous carcinogenesis

Gynecologic oncology, 2013-12, Vol.131 (3), p.555-560

2013

Volltextzugriff (PDF)

PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy

Journal of hematology and oncology, 2013-08, Vol.6 (1), p.60-60, Article 60

2013

Volltextzugriff (PDF)

Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer

Clinical cancer research, 2012-05, Vol.18 (9), p.2668-2678

2012

Volltextzugriff (PDF)

Resection of lymph node metastases influences survival in stage IIIC endometrial cancer

Gynecologic oncology, 2005-12, Vol.99 (3), p.689-695

2005

Volltextzugriff (PDF)

Struma ovarii simulating ovarian sertoli cell tumor: a case report with literature review

International journal of clinical and experimental pathology, 2013-01, Vol.6 (3), p.516-520

2013

Volltextzugriff (PDF)

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

The lancet oncology, 2017, Vol.18 (1), p.75-87

2017

Volltextzugriff (PDF)

Amniotic fluid embolism presenting after uterine manipulation under general anesthesia: A case with a positive outcome

Resuscitation, 2008-04, Vol.77 (1), p.145-146

2008

Volltextzugriff (PDF)

Delay in treatment of invasive cervical cancer due to intimate partner violence

Gynecologic oncology, 2005-11, Vol.99 (2), p.507-509

2005

Volltextzugriff (PDF)

Incidence of hypersensitivity reactions to carboplatin or paclitaxel in patients with ovarian, Fallopian tube, or primary peritoneal cancer with or without BRCA1 or BRCA2 mutations

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e18758-e18758

2018

Volltextzugriff (PDF)

Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL

Clinical cancer research, 2019-11, Vol.25 (22_Supplement), p.GMM-048-GMM-048

2019

Volltextzugriff (PDF)

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5513-5513

2019

Volltextzugriff (PDF)

Pelvic Lymph Node Count is an Important Prognostic Variable for FIGO Stage I and II Endometrial Carcinoma With High-Risk Histology

Obstetrical & gynecological survey, 2006-10, Vol.61 (10), p.642-644

2006

Volltextzugriff (PDF)

Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL

Clinical cancer research, 2017-06, Vol.23 (11_Supplement), p.AP27-AP27

2017

Volltextzugriff (PDF)

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5549-5549

2016

Volltextzugriff (PDF)

Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5540-5540

2016

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)
Berichte
(1)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer

Assessment of the Role of Intraoperative Frozen Section in Guiding Surgical Staging for Endometrial Cancer

MRI of ovarian torsion: Correlation of imaging features with the presence of perifollicular hemorrhage and ovarian viability

The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations

Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma

Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review

Tubal origin of ovarian endometriosis

Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology

Secretory cell expansion with aging: Risk for pelvic serous carcinogenesis

PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy

Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer

Resection of lymph node metastases influences survival in stage IIIC endometrial cancer

Struma ovarii simulating ovarian sertoli cell tumor: a case report with literature review

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Amniotic fluid embolism presenting after uterine manipulation under general anesthesia: A case with a positive outcome

Delay in treatment of invasive cervical cancer due to intimate partner violence

Incidence of hypersensitivity reactions to carboplatin or paclitaxel in patients with ovarian, Fallopian tube, or primary peritoneal cancer with or without BRCA1 or BRCA2 mutations

Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study

Pelvic Lymph Node Count is an Important Prognostic Variable for FIGO Stage I and II Endometrial Carcinoma With High-Risk Histology

Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial

Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC)

Suchergebnisse filtern